G3 WAVE AVEO GAS 96534241 OEM NEW DOOR FILLER FUEL LATCH DOOR TANK Car & Truck Interior Door Panels & Parts


  1. Home
  2. G3 WAVE AVEO GAS 96534241 OEM NEW DOOR FILLER FUEL LATCH DOOR TANK
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
AVEO WAVE G3 GAS TANK DOOR LATCH FUEL FILLER DOOR NEW OEM  96534241
Condition: New Genuine OEM: Yes
Fitment Type: Direct Replacement Warranty: Other
Category 3: Fuel Door Quantity: 1
Item Name: Lock SKU: 204:96534241
Part Ref# on Diagram: ONLY PART REFERENCE #10 ON THE DIAGRAM IS INCLUDED Brand:

GM

Quantity Needed: 1 Manufacturer Part Number:

96534241

Category 1: Body Hardware Category 2: Fuel Door
Placement on Vehicle: Rear UPC:

Does not apply




published on tue nov 09 2021

G3 WAVE AVEO GAS 96534241 OEM NEW DOOR FILLER FUEL LATCH DOOR TANK Car & Truck Interior Door Panels & Parts

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

G3 WAVE AVEO GAS 96534241 OEM NEW DOOR FILLER FUEL LATCH DOOR TANK Car & Truck Interior Door Panels & Parts

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS